Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of XJN010 nasal spray for intermittent treatment of OFF episodes in adults with Parkinson's disease
CTR20253290Phase 2Active
- Sponsor
- Xinji Pharma
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XJN010 in Parkinson's disease (PD), sponsored by Xinji Pharma. Started Sep 2025; status: active.
02
Drugs
XJN010
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20253290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253290.